Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 295 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Extensive Stage Lung Small Cell Cancer Clear all
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
Interventions
23ME-00610
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
12 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00003299
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

NCT00019006
View directory record Official record
Conditions
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions
Detox-B adjuvant, ras peptide cancer vaccine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00004095
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00182689
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 23, 2026, 4:46 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

NCT07057791
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Cancer
Interventions
Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00227565
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, pemetrexed disodium, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
148
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 97 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Not applicable Interventional Results available

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer

NCT03607682
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Tumor Treating Fields (TTF) Therapy, NovoTTF-200A Device, Quality-of-Life Assessment
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
22 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1Phase 2 Interventional

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

NCT03371979
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Pegzilarginase, Pembrolizumab
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

NCT00387660
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, irinotecan
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Interventions
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Drug
Lead sponsor
Ariceum Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT00253383
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer

NCT00045162
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, irinotecan hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
406
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 273 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

NCT04702880
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
BMS-986012, Carboplatin, Etoposide, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 4:46 PM EDT
Recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab govitecan, Atezolizumab, Durvalumab
Drug
Lead sponsor
Bindu R Potugari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

NCT01076504
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Amrubicin, Carboplatin, Pegfilgrastim
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
20
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Lakeland, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 23, 2026, 4:46 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

NCT04728230
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Durvalumab, Etoposide, Olaparib, Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT00087048
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

NCT00617409
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA)
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 23, 2026, 4:46 PM EDT